Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tucaresol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tucaresol tablets 25 mg | DRUG | - |
Inclusion Criteria: * Currently on licensed triple combination therapy, which is defined as two nucleoside analogues (2 NRTI) (excluding Abacavir) and a protease inhibitor (PI) (including boosted PI regimens) or non nucleoside reverse transcriptase inhibitor (NNRTI). * Must be on the same treatment...
Top 20 of 28 competitors
Tucaresol is an investigational small molecule being studied for the treatment of HIV Infection. It is being evaluated as an add-on therapy to highly active antiretroviral therapy (HAART) in adults with chronic HIV-1 infection. The drug is currently in Phase 2 clinical development.
Tucaresol is being developed by GSK plc, a global biopharmaceutical company. GSK is listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of Tucaresol in patients with HIV infection.
Tucaresol is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for its potential use in treating HIV infection.
Tucaresol has been studied in one clinical trial, identified as NCT00343941. This Phase 2 trial, titled 'Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults', was a randomized, double-blind study that has been completed. The trial enrolled 45 participants in Italy.
Tucaresol is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by GSK plc and is currently in Phase 2 clinical trials for the treatment of HIV infection.